Neoadjuvant Chemotherapy for Pediatric Synovial Sarcoma

Rationale for Chemotherapy-Sensitive Histology

Synovial sarcoma is recognized as one of the relatively chemotherapy-sensitive soft tissue sarcoma subtypes in pediatric patients, distinguishing it from less responsive adult-type sarcomas, with response rates observed in both localized and metastatic disease with anthracycline- and ifosfamide-based treatment justifying aggressive chemotherapy in this population, according to the American Society of Clinical Oncology 1, 2

The European Society for Medical Oncology recommends multiagent chemotherapy with anthracyclines plus ifosfamide as the treatment of choice when tumor response can provide clinical advantage and performance status is good, achieving higher response rates compared to single-agent doxorubicin, particularly in chemotherapy-sensitive histological types like synovial sarcoma 3, 4
Doxorubicin should be administered at 75 mg/m² per cycle, which is the standard anthracycline dose, according to the European Society for Medical Oncology 3, 4
Ifosfamide should be administered at 9-10 g/m² per cycle divided over 3-5 days, which is the standard dosing in pediatric protocols, according to the European Society for Medical Oncology 3, 4
Chemotherapy cycles should be administered every 3 weeks, with 3-4 cycles before reassessment and surgery, according to the European Society for Medical Oncology 3, 4

Chemotherapy is preferably given before surgery to assess tumor response and modulate treatment length, allowing evaluation of chemosensitivity and facilitating surgical resection, according to the European Society for Medical Oncology 3, 4
The cumulative dose of doxorubicin must be monitored to minimize cardiotoxic effects, particularly important in pediatric patients with long life expectancy, as recommended by the American Heart Association 5
Treatment should be performed in specialized sarcoma centers with experience in pediatric soft tissue sarcomas and multimodal therapy, as recommended by the National Comprehensive Cancer Network 5
Chemotherapy must be given by teams experienced in aggressive and toxic protocols with provision of full medical and hematological supportive care, according to the British Journal of Cancer 6